CTOs on the Move

scPharmaceuticals

www.scpharmaceuticals.com

 
scPharmaceuticals, based in Lexington, MA, is a privately held biopharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. Based on widely used generic drugs that currently require intravenous or intramuscular injections, our innovative products will be administered subcutaneously via a proprietary patch pump. This avoids material risks and costs associated with the current delivery options. Our lead products are the first subcutaneous formulations of furosemide (the most widely used parenteral diuretic in treating heart failure) and ceftriaxone (the most widely used parenteral antibiotic outside the hospital setting). Our novel furosemide formulation enables convenient anytime anywhere use, for ...
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

scPharmaceuticals raised $45.6M on 01/04/2017
scPharmaceuticals raised $65M on 05/18/2020

Similar Companies

Community Medical Center, Inc

CMC's Department of Pediatrics and the hospital's administration are committed to quality care for children, said Steve Carlson, CMC's president and chief executive officer.

PlasmaCare

PlasmaCare is a Hampton, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bruce Leeb and Company

Bruce Leeb and Company is a Fair Lawn, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.

Georgetown Health Care Ctr

Georgetown Health Care Ctr is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.